MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

Official Title

An open-label, multicenter, non-randomized phase 2 study of elranatamab monotherapy in participants with multiple myeloma who are refractory to at least one proteasome inhibitor, one immunomodulatory drug and one anti-CD38 antibody

Summary:

The purpose of the study is to evaluate whether single-agent Elranatamab (PF-06863135) can provide clinical benefit in participants with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody: binding of Elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.

Trial Description

Primary Outcome:

• objective response rate

• duration of response
• cumulative complete response rate
• duration of cumulative complete response
• progression free survival
• time to response
• minimal residual disease negativity rate
• frequency of treatment-emergent adverse events
• frequency of laboratory abnormalities
• concentrations of elranatamab (PF-06863135)
• immunogenicity of elranatamab (PF-06863135)
• overall survival

View this trial on ClinicalTrials.gov